

from five patients (11.9%) as having 2–5 bands patterns with hybridization patterns of 2–5 copies. However, the isolates of two of these patients (5%) had non-identical patterns. One of these patient's isolates had a 2–5 bands pattern in the first and a Beijing pattern in the second registration, whereas the other's isolates had the Beijing pattern in the first and a 2–5 bands pattern in the second registration. In isolates from the patients with three TB registrations, recurrent IS6110-RFLP patterns were identical patterns of Beijing family type in six patients, Nonthaburi family in one and single band pattern in one.

### Insertion sequence 6110-restriction fragment length polymorphism patterns and drug resistance

When we analyzed anti-TB drug resistance in relation to IS6110-RFLP patterns (Table 4), we most commonly found monodrug resistance in isolates with the Beijing family pattern (8/12). The other monodrug resistant isolates had single-band patterns (two isolates), the Nonthaburi family pattern (one) and a heterogeneous pattern (one). We found polydrug resistance in isolates with Beijing family pattern (3/5) and single band pattern (2/5). We found MDR-TB in four, eight and one isolates with identical patterns in first, second and third registrations, respectively. One isolate with a non-identical pattern had MDR-TB at the first and second registrations. We commonly found MDR-TB strains in isolates with Beijing family patterns (10/15); the rest were heterogeneous (one isolate) and 2–5 bands (four). For all treatment outcomes, the strains that had been treated on the first registration were most often the cause of recurrent TB, as shown by their identical patterns, in which the Beijing family was predominant. We found acquired MDR (resistance in those who have previously undergone TB treatment) in *M. tuberculosis* of the Beijing family. Of these, two isolates had primary drug resistance (resistance without a history of previous treatment) in the first registration whereas there were six MDR-TB isolates in the second registration. Four of these isolates had acquired MDR. The time intervals between the first and subsequent registrations varied.

## DISCUSSION

In this study, we analyzed anti-TB drug resistance and IS6110-RFLP patterns of *M. tuberculosis* strains from recurrent patients in their first, second and third TB registrations. Resistance to INH, RMP, EMB and SM occurred more frequently in *M. tuberculosis* strains from the second registrations than in those from the first. The MDR rate was 12.2% among new cases at first registration, 22.5% among recurrent cases with previously treated TB at the second registration and 12.5% at third registration, indi-

cating higher rate of drugs resistance in recurrent TB. In the present study, we found resistance to INH or RMP, with or without resistance to any other drugs (MDR-TB), more commonly in patients with failure and default treatment. Moreover, two acquired MDR-TB isolates from retreatment patients after treatment failure developed resistance to all anti-TB drugs tested (RMP, INH, Sm and EMB). These strains could well develop XDR-TB eventually. Recently, it has been recognized that MDR-TB and XDR-TB are serious problems for TB control program because XDR-TB strains are virtually untreatable (22). There is evidence that inadequate treatment is the main cause of endogenous reactivation, which is likely to occur soon after completion of treatment for the first episode (23). However, apparently successful treatment sometimes fails to totally eradicate the bacteria from patients; they can then reactivate later. TB patients who fail primary treatment have significantly greater risks of any drug resistance or MDR-TB than do those with successfully complete treatment (treatment completion or cure) (24). There is evidence that irregular drug administration causes development of drug resistance during short-course therapy with multiple drugs, because the drugs are taken for only a few killing cycles and regrowth occurs when the drugs stop. During each cycle, it is possible that selection of mutants that are relatively resistant occurs (25). We found significant differences in monodrug resistance to isoniazid or rifampin and MDR among *M. tuberculosis* strains from primary and secondary registrations, which could be attributable primarily due to poorly administered TB treatment (1). Recurrent TB is common in patients who have failed to respond to first and second line drugs (26). In line with this, our findings that MDR-TB occurs most commonly in patients with failure and default treatment and rarely in those with previously successful treatment (complete and cure) imply that failure of previous treatment is associated with drug resistance. Therefore, in areas with a high prevalence of drug resistance, we recommend use of alternative regimens, especially during the continuation phase. Drug resistant TB is a man-made phenomenon; inadequate or poorly administered treatment regimens can allow drug-resistant strains to become dominant in patients with TB (1).

In general, there is a very high rate of unexplained recurrent TB in areas with a high incidence of TB (27). Endogenous reactivation is possibly the main cause of relapses after a period without TB and recurrent TB requiring retreatment in Chiang Rai province, an area with high prevalence of TB and a high proportion of drug resistance (10). In this study, endogenous reactivation (30/42, 71.4%) was the major cause of recurrent TB either from relapse or retreatment as evidenced by identical IS6110-RFLP of Beijing (21/42, 50%), Nonthaburi (3/42, 7.1%)

**Table 4.** The relationship between anti-TB drug resistance and IS6110- RFLP patterns

IS6110- RFLP patterns	Resistant isolates								
	Mono drug			Poly drugs			MDR		
	First	Second	Third	First	Second	Third	First	Second	Third
Single band	1	1	0	0	1	1	0	0	0
2–5 bands	0	0	0	0	0	0	2	2	0
Beijing	4	3	1	2	0	1	3	6	1
Nonthaburi	0	0	1	0	0	0	0	0	0
Heterogeneous	1	0	0	0	0	0	0	1	0

and heterogeneous (6/42, 14.3%) patterns in a large proportion of isolated strains. The classical IS6110-RFLP method fails to adequately differentiate *M. tuberculosis* strains with identical patterns of low copy numbers of IS6110 with 2–5 band (5/42, 11.9%) and single band patterns (5/42, 11.9%) (28). Other strain typing methods such as VNTR typing are required to infer epidemiological linkage between low-copy number isolates (28). However, VNTR typing systems cannot define all unique isolates. If the primary genotype is IS6110-RFLP, VNTR typing is certainly useful as a secondary means of typing *M. tuberculosis* with small copy numbers of IS6110. (28). It is possible that the identical IS6110-RFLP patterns that we found in first and subsequent TB registrations did not truly represent endogenous reactivation because these patterns appearances may have reflected the duration of the study, incidence of *M. tuberculosis* strains in the population and prevalence of dominant strains. Therefore, we recommend further comprehensive investigation of the prevalence of IS6110-RFLP patterns among *M. tuberculosis* strains from this set of patients during 1997 through 2006 to determine the proportion of these strains in recurrent TB.

The non-identical IS6110-RFLP patterns observed in two retreatment patients after failure could be caused by either exogenous re-infection (2/42, 5%) with new *M. tuberculosis* strains or mixed infection, which reportedly occurs after successful treatment (29, 30) and even during treatment (30). Exogenous re-infection plays a dominant role in the pathogenesis of post-primary TB in areas with a high incidence of the disease such as in South Africa and China (30, 31). Simultaneous infection with multiple strains of *M. tuberculosis* can cause exogenous reinfection of patients: this provides further evidence for occurrence of reinfection (32).

We found that the Beijing family IS6110-RFLP pattern predominated among strains causing recurrent TB (50%). The rest of the isolates belonged to the Nonthaburi family, were heterogeneous, or had 2–5 band or single band patterns. These findings are quite different from those of a previous study in which the Beijing family was not the pre-

dominant pattern in northern Thailand, comprising only 17.7% of isolates) (13). The prevalence rates of Beijing strain in other geographical areas is diverse, for example being 42% in Bangkok, 27.9% in central and 31.3% in western Thailand (13). However, such discrepancies may be attributable to previous studies including all forms of pulmonary TB without differentiating between different histories of anti-TB treatment. In this study, the major patterns in MDR-TB belonged to the Beijing family, the rest being heterogeneous and having 2–5 bands. Additionally, isolates with acquired MDR evidenced identical IS6110-RFLP patterns of the Beijing family, suggesting its strong association with response to treatment (14, 15). In Germany, where the incidence of TB is steadily decreasing and the estimated overall percentage of MDR-TB is less than 3% of all TB cases, researchers have found similar evidence for Beijing genotypes among MDR-TB strains (33). A study in Thailand between 1996 and 2007 proposed a classification of ancestral and modern Beijing sublineages based on the VNTR in which they identified 78.8% as modern Beijing strains and the remaining 21.2% as ancestral Beijing isolates (34). Although researchers have further analyzed such data and combined it with those of previous studies to construct a comprehensive phylogenetic tree, they have not assessed linkage between TB treatment history and development of drug resistance (34). Therefore, we recommend further comprehensive investigation of the genetic diversity and evolution of the Beijing genotype in *M. tuberculosis* isolates from patients with recurrent TB.

## ACKNOWLEDGMENTS

We thank the participating patients for their kind participation in this study and staff of the Chiang Rai provincial hospital and the National TB Reference Laboratory, Bureau of Tuberculosis, Bangkok for their technical support. This work was supported by Health and Labor Science Research Grants for Research on Emerging and Re-emerging Infectious Diseases (H17-shinko-021 and

H20-shinko-014), Ministry of Health, Labor and Welfare, Japan; the TB/HIV Research Project, Thailand, a collaborative research project between the Research Institute of Tuberculosis and the Japan Anti-tuberculosis Association; and the Faculty of Tropical Medicine, Mahidol University.

## DISCLOSURE

There is no conflict of interest for any of the authors of the manuscript caused by financial, commercial or other affiliations.

## REFERENCES

- World Health Organization. (2008) *Drug resistant tuberculosis in the South-East Asia region Status Report*. New Delhi: Regional Office for South-East Asia, pp. 1–9.
- World Health Organization. TB in South-East Asia, Epidemiology of TB in the Region. 1 December 2011. Available from: [http://www.searo.who.int/en/Section10/Section2097/Section2100\\_14803.htm](http://www.searo.who.int/en/Section10/Section2097/Section2100_14803.htm)
- Jittimane S., Vorasingha J., Mad-asin W., Nateniyom S., Rienthong S., Varma J.K. (2009) Tuberculosis in Thailand: epidemiology and program performance, 2001–2005. *Int J Infect Dis* 13: 436–42.
- Anyama N., Sseguya S., Okwera A., A El-Naggar W., Mpagi F., Owino E. (2007) The challenge of retreatment pulmonary tuberculosis at two teaching and referral hospitals in Uganda. *African Health Sciences* 7(3): 136–42.
- Centers for Disease Control and Prevention. (2003) Update: Treatment of tuberculosis/CDC recommendations and reports. *MMWR* 52(RR-11): 1–80.
- Canetti G., Sutherland I., Svandova E. (1972) Endogenous reactivation and exogenous reinfection: their relative importance with regard to the development of non-primary tuberculosis. *Bull Int Union Tuberc* 47: 116–34.
- Chaves F., Dronca F., Alonso-Sanz M., Noriega A.R. (1999) Evidence of exogenous reinfection and mixed infection with more than one strain of *Mycobacterium tuberculosis* among Spanish HIV-infected inmates. *AIDS* 13(5): 615–20.
- Bandera A., Gori A., Catozzil L., Degliesposti A., Marchetti G., Molteni C. (2001) Molecular epidemiology study of exogenous reinfection in an area with a low incidence of tuberculosis. *J Clin Microbiol* 39(6): 2213–8.
- Connolly C., Reidb A., Davies G., Sturm W., McAdam K.P., Wilkinson D. (1999) Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa. *AIDS* 13: 1543–47.
- Yoshiyama T., Yanai H., Rhiengthong D., Palittapongarnpim P., Nampaisan O., Supawitkul S., Uthaiworawit W., Mori T. (2004) Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. *Int J Tuberc Lung Dis* 8(1): 31–38.
- van Embden J.D., Cave M.D., Crawford J.T., Dale J.W., Eisenach K.D., Gicquel B., Hermans P., Martin C., McAdam R., Shinnick T.M. (1993) Strain Identification of *Mycobacterium tuberculosis* by DNA fingerprinting: Recommendations for a standardized methodology. *J Clin Microbiol* 31(2): 406–9.
- McEvoy C.R., Falmer A.A., van Pittius N.C., Victor T.C., van Helden P.D., Warren R.M. (2007) The role of IS6110 in the evolution of *Mycobacterium tuberculosis*. *Tuberculosis* 87: 393–404.
- Rienthong D., Ajawatanawong P., Rienthong S., Smithtikarn S., Akarasewi P., Chairpresert A., Palittapongarnpim P. (2005) Restriction fragment length polymorphism study of nationwide samples of *Mycobacterium tuberculosis* in Thailand, 1997–1998. *Int J Tuberc Lung Dis* 9(5): 576–81.
- Glynn J.R., Whiteley J., Bifani P.J., Kremer K., Soolingen V.D. (2002) Worldwide occurrence of Beijing/W strains of *Mycobacterium tuberculosis*: A systematic review. *Emerg Infect Dis* 8(8): 843–9.
- Lillebaek T. (2005) The molecular epidemiology of tuberculosis. *Dan Med Bull* 52: 143–59.
- Sun Y.J., Lim T.K., Yeow Ong A.K., Heng Ho B.C., Seah G.T., Paton N. (2006) Tuberculosis associated with *Mycobacterium tuberculosis* Beijing and non-Beijing genotypes: a clinical and immunological comparison. *BMC Infect Dis* 6: 105.
- World Health Organization. *WHO Library Cataloguing in Publication Data: Treatment of tuberculosis: guidelines fourth edition*. WHO/HTM/TB/2009. 420. Available from: [http://www.who.int/tb/publications/tb\\_treatmentguidelines/en/index.html](http://www.who.int/tb/publications/tb_treatmentguidelines/en/index.html).
- Glynn J.R., Yates M.D., Crampin A.C., Ngwira B.M., Mwaungulu F.D., Black G.E., Chaguluka S.D., Mwafalirwa D.T., Floyd S., Murphy C., Drobniewski F.A., Fine P.E. (2004) DNA fingerprint changes in tuberculosis: reinfection, evolution, or laboratory error? *J Infect Dis* 190: 1158–66.
- van Soolingen D., de Haas P.E., Blumenthal R.M., Kremer K., Sluijter M., Pijnenburg J.E., Schouls L.M., Thole J.E., Dessens-Kroon M.W., van Embden J.D., Hermans P.W. (1996) Host-mediated modification of *PvuII* restriction in *Mycobacterium tuberculosis*. *J Bacteriol* 178(1): 78–84.
- Palittapongarnpim P., Luangsook P., Tansuphaswadikul S., Chuchottaworn C., Prachtkam R., Sathapatayavongs B. (1997) Restriction fragment length polymorphism study of *Mycobacterium tuberculosis* in Thailand using IS6110 as probe. *Int Tuberc Lung Dis* 1(4): 370–6.
- Mazurek H.G., Cave M.D., Eisenach K.D., Wallace R.J., Bates J.H., Crawford J.T. (1991) Chromosomal DNA fingerprint patterns produced with IS6110 as strain-specific markers for epidemiologic study of tuberculosis. *J Clin Microbiol* 29(9): 2030–3.
- World Health Organization. (2006) Guideline for the programmatic management of drug-resistant tuberculosis. Update 2011.
- Nettles R.E., Mazo D., Alwood K., Gachuhi R., Maltas G., Wendel K., Cronin W., Hooper N., Bishai W., Sterling T.R. (2004) Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. *HIV/AIDS CID* 38(1): 731–6.
- Churchyard G.J., Corbett E.L., Kleinschmidt I., Mulder D., Cock D.K.M. (2003) Drug-resistant tuberculosis in South African gold miners: incidence and associated factors. *Int J Tuberc Lung Dis* 4(5): 433–40.
- Mitchison D.A. (1998) How resistance emerge as a result of poor compliance during short course chemotherapy for tuberculosis. *Int J Tuberc Lung Dis* 2: 10–5.
- Kritski A.L., Rodrigues de Jesus L.S., Andrade M.K., Werneck-Barroso E., Vieira M.A., Hoffner A., Riley L.W. (1997) Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes. *Chest* 111: 1162–7.
- Verver S., Warren R.M., Beyers N., Richardson M., van der Spuy G.D., Borgdorff M.W., Enarson D.A., Behr M.A., van Helden P.D. (2005) Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. *Am J Respir Crit Care Med* 171(12): 1430–35.
- Thong-On A., Smittipat N., Juthayothin T., Yanai H., Yamada, Yorsangsukkamol J., Chairprasert A., Rienthong D., Billamas P., Palittapongarnpim P. (2010) Variable-number tandem repeats

- typing of *Mycobacterium tuberculosis* isolates with low copy numbers of IS6110 in Thailand. *Tuberculosis* **90**: 9–15.
29. Small P.M., Shafer R.W., Hopewell P.C., Singh S.P., Murphy M.J., Desmon E., Sierra M.F., Schoolnik G.K. (1993) Exogenous reinfection with multidrug resistant *Mycobacterium tuberculosis* in patients with advanced HIV infection. *N Engl J Med* **328**: 1137–44.
  30. van Rie A., Warren R., Richardson M., Victor T.C., Gie R.P., Enarson D.A., Bevers N., van Helden P.D. (1999) Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. *N Engl J Med* **341**(16): 1174–9.
  31. Shen G., Xue Z., Shen X., Sun B., Gui X., Shen M., Mei J., Gao Q. (2006) Recurrent tuberculosis and exogenous reinfection, Shanghai, China. *Emerg Infect Dis* **12**(11): 1776–8.
  32. Chiang C.Y., Riley L.W. (2005) Exogenous reinfection in tuberculosis. *Lancet Infect Dis* **5**: 629–36.
  33. Kobinica T., Rusch-Gerdes S., Niemann S. (2004) The Beijing genotype is emerging among multidrug-resistant *Mycobacterium tuberculosis* strains from Germany. *Int Tuberc Lung Dis* **8**(9): 1107–13.
  34. Faksri K., Drobniewski F., Nikolayevskyy V, Brown T., Prammananan T., Palittapongarnpim P, Prayoonwiwat N., Chaiprasert A. (2011) Genetic diversity of the *Mycobacterium tuberculosis* Beijing family based on IS6110, SNP, LSP and VNTR profiles from Thailand. *Infection, Genetics and Evolution* **11**: 1142–49.

## Association of *IFNGR2* gene polymorphisms with pulmonary tuberculosis among the Vietnamese

Minako Hijikata · Junko Shojima · Ikumi Matsushita · Katsushi Tokunaga · Jun Ohashi · Nguyen T. L. Hang · Toru Horie · Shinsaku Sakurada · Nguyen P. Hoang · Pham H. Thuong · Luu T. Lien · Naoto Keicho

Received: 16 August 2011 / Accepted: 24 October 2011 / Published online: 6 November 2011  
© The Author(s) 2011. This article is published with open access at Springerlink.com

**Abstract** Interferon- $\gamma$  (IFN- $\gamma$ ) is a key molecule of T helper 1 (Th1)-immune response against tuberculosis (TB), and rare genetic defects of IFN- $\gamma$  receptors cause disseminated mycobacterial infection. The aim of the present study was to investigate whether genetic polymorphisms found in the Th1-immune response genes play a role in TB. In our study, DNA samples were collected from two series of cases including 832 patients with new smear-positive TB and 506 unrelated individuals with no history of TB in the general

population of Hanoi, Vietnam. Alleles of eight microsatellite markers located around Th1-immune response-related genes and single nucleotide polymorphisms near the promising microsatellites were genotyped. A set of polymorphisms within the interferon gamma receptor 2 gene (*IFNGR2*) showed a significant association with protection against TB ( $P = 0.00054$ ). Resistant alleles tend to be less frequently found in younger age at diagnosis ( $P = 0.011$ ). Luciferase assays revealed high transcriptional activity of the promoter segment in linkage disequilibrium with resistant alleles. We conclude that the polymorphisms of *IFNGR2* may confer resistance to the TB development of newly infected individuals. Contribution of the genetic factors to TB appeared to be different depending on age at diagnosis.

**Electronic supplementary material** The online version of this article (doi:10.1007/s00439-011-1112-8) contains supplementary material, which is available to authorized users.

M. Hijikata · J. Shojima · I. Matsushita · S. Sakurada · N. Keicho (✉)

Department of Respiratory Diseases, Research Institute, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan  
e-mail: nkeicho-ky@umin.ac.jp

K. Tokunaga  
Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan

J. Ohashi  
Molecular and Genetic Epidemiology, Department of Public Health Medicine, Doctoral Program in Life System Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki 305-8077, Japan

N. T. L. Hang  
NCGM-BMH Medical Collaboration Center, Hanoi, Vietnam

T. Horie  
JICA-Guatemala Chagas Disease Project, Guatemala City, Guatemala

N. P. Hoang · P. H. Thuong · L. T. Lien  
Hanoi Lung Hospital, Hanoi, Vietnam

### Introduction

Tuberculosis (TB) remains one of the major health problems worldwide (Lopez et al. 2006): According to an estimate, approximately one-third of the world's population is infected with *Mycobacterium tuberculosis* (*M. tuberculosis*), and more than 9 million people develop active TB disease every year. Of these patients, 80% are from 22 high-burden countries including Vietnam (World Health Organization 2010).

Development of TB has been considered to be a two-stage process, infection with *M. tuberculosis* and progression to disease. In total, 5–10% of immunocompetent individuals initially infected with *M. tuberculosis* develop active TB during their lifetime (Frieden et al. 2003). When young vulnerable individuals fail to inhibit growth of the pathogen, they often develop the disease within 2 years of infection. In the remaining individuals, containment of *M. tuberculosis* is successful, though the agent is not

eliminated completely, which leads to life-long latent infection (Russell 2007). When immune levels are impaired after years of infection, reactivation of dormant bacteria leads to disease manifestation, which contributes to the development of elderly TB, though new TB patients affected by re-infection also have to be taken into account (Tufariello et al. 2003). Protective immunity to control the initial infection, orchestrated by immune cells including T cells and macrophages, is influenced by a variety of factors including genetic predisposition (Möller et al. 2010a).

T helper 1 (Th1)-type immune system is crucial to protection against mycobacterial diseases, in which interferon- $\gamma$  (IFN- $\gamma$ ) has a key role (Lin and Flynn 2010). Although T cell response to mycobacterial infection in human beings is difficult to be addressed experimentally (Cooper 2009), it is known that genetic defects of Th1 molecules can be found in genes such as interferon gamma receptor 1 (*IFNGR1*), interferon gamma receptor 2 (*IFNGR2*), signal transducer and activator of transcription 1, 91 kDa (*STAT1*), interleukin 12B (*IL12B*) and interleukin 12 receptor, beta 1 (*IL12RB1*) cause severe mycobacterial diseases (Zhang et al. 2008). These observations have highlighted IFN- $\gamma$ /interleukin-12 (IL-12) axis and their polymorphisms have been investigated in mycobacterial infection: association of promoter polymorphism in *IFNGR1* with TB was reported in African populations in independent studies, whereas association of *IFNGR2* with TB has not been published in the literature (Cooke et al. 2006; Stein et al. 2007). Associations with *IL12B* and *IL12RB1* were not consistently shown (Möller et al. 2010b). In the present study, we analyzed genetic polymorphisms of major Th1 cytokine receptors (*IFNGR1*, *IFNGR2*, *IL12RB1* and *IL12RB2*) and signal transduction molecules (*STAT1* and *STAT4*) in Hanoi-Vietnamese and reported a disease association and functional significance of polymorphisms in *IFNGR2*.

## Materials and methods

### Study population

The patients and control subjects were recruited in Hanoi, Vietnam (Horie et al. 2007). In total, 832 smear-positive pulmonary TB patients without previous episodes of TB (age  $41 \pm 14.4$ , males 77.6%) and 506 healthy volunteers without previous and present history of TB (age  $37 \pm 10.3$ , males 50.0%) participated in this study. All of them were unrelated Hanoi, Vietnamese. TB patients were all recruited immediately after the diagnosis was made. The TB panel A ( $n = 277$ , age  $41 \pm 13.5$ , males 73.3%) was collected in 2003–2004, and the second TB panel B ( $n = 555$ , age  $41 \pm 14.8$ , males 79.8%) was collected in

2007–2009. Pulmonary physicians diagnosed all the patients as new active pulmonary TB and treated them with anti-TB drugs based on the guidelines of the national TB program. Informed consent was obtained from all participants. The study protocol was approved by the ethics committees of the Ministry of Health, Vietnam and the National Center for Global Health and Medicine, Japan. Since 4 patients in panel A were human immunodeficiency virus (HIV) positive by previously described PCR assay (Panteleeff et al. 1999) with minor modifications and 49 patients in panel B were HIV seropositive (Hang et al. 2011), they were excluded from further analysis.

### Microsatellite markers

We used eight microsatellite markers (*IFNGR1*-MS1, *IFNGR2*-MS1, *IFNGR2*-MS2, *IL12RB1*-MS1, *IL12RB2*-MS1, *IL12RB2*-MS2, *STAT1*-MS1 and *STAT4*-MS1) located in the major Th1-immune response genes (Tanaka et al. 2005) for screening of genetic polymorphisms associated with active TB. A part of the samples, 98 TB patients from the TB panel A and 200 controls were analyzed as described under (Tanaka et al. 2005).

### Single nucleotide polymorphisms (SNP) screening in *IFNGR2* of Vietnamese samples

Forty-eight control samples were subjected to PCR amplifications of promoter and seven exon regions of *IFNGR2* and their sequences were analyzed for polymorphisms. GC content of genomic sequence upstream of the translation initiation codon was high (78.2% of nucleotides  $-1$  to  $-500$ ), and PCR condition was optimized for GC-rich template. The genomic DNA was extracted from anticoagulated blood with QIAamp DNA midi kit (QIAGEN, Hamburg, Germany). PCR was performed using TaKaRa LA Taq with GC buffer I (TaKaRa, Shiga, Japan) with primers 5'-CTCC CAACAGGCGTCAAACGACATGGTG-3' and 5'-TGGTC CCTGCTCCACCGCTGCTACTACAAA-3'. PCR cycling condition was 40 cycles of 95°C for 30 s, 67°C for 30 s and 72°C for 2 min. Amplified products (1,607 bp) were purified and sequenced with BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) using 3100 Genetic Analyzer (Applied Biosystems), with primers 5'-AGCTTAATATGTACTTTGGGG-3' and 5'-CACCCACTCTGAGCACCCGG-3'. This method was also used for the typing of three promoter SNPs, rs8134145, rs8126756 and rs17882748. Sequencing primers that have the allelic variant at their 3'-end 5'-GGAGGGGTGGGGC TCCAGGGAAA-3', 5'-GCAGGGCCCGCCTCTTCCCGA GCA-3' and 5'-GGGCTCCAGGGAAAGCCCCGGGGT-3' were also designed, and allele-specific sequencing was

performed to directly determine the haplotypes of the three promoter SNPs.

#### Selection of representative SNPs around *IFNGR2* and genotyping

Representative SNPs around *IFNGR2* were selected from HapMap database (The International HapMap Consortium 2005). SNP genotype data of Han Chinese in Beijing (CHB) encompassing 350 kb from *IL10RB* to *CRYZL1* were analyzed by Haploview 4.2 (Barrett et al. 2005), and 27 representative SNPs were chosen based on the method of block-by-block tags in linkage disequilibrium (LD) blocks determined by confidence interval method (Gabriel et al. 2002). The *IFNGR2* SNPs identified as mentioned above and selected SNPs were genotyped in 273 TB patients of panel A and 506 controls. Genotyping was performed by the Digitag2 assay that has previously been described in another study (Nishida et al. 2007).

#### Rapid amplification of cDNA end (5'-RACE) of *IFNGR2*

The exact 5' end of exon 1 was confirmed with FirstChoice RLM-RACE Kit (Ambion, Austin, TX, USA) using total RNA of THP-1 cells (ATCC TIB-202) stimulated with 10 ng/ml of phorbol myristate acetate (Schwende et al. 1996), U937 cells (ATCC CRL-1593.2) and Jurkat cells (ATCC TIB-152).

#### Luciferase assay

Promoter region of *IFNGR2* (Rhee et al. 1996) consisting of 1,167 bp (position -1,172 to -6 of initiation codon) was amplified by PCR and inserted into *Xho* I and *Bgl* II sites of pGL4.10 vector (Promega, Madison, WI, USA). Three plasmids of the observed haplotypes (CCC, ATC, ATT of rs8134145, rs8126756 and rs17882748) were constructed, and their sequences were confirmed to be devoid of any additional nucleotide difference. Reporter plasmids were mixed with pRL-TK (Promega) and transfected to Jurkat human T-cell leukemia cells with Lipofectamin LTX (Invitrogen, Carlsbad, CA, USA) in triplicate. Cells were harvested after 24 h and luciferase activity was measured using Dual-Luciferase Reporter Assay System (Promega). The transfection experiments were repeated twice with three independent subclones of each plasmid.

#### Statistical analysis

Disease associations with markers were assessed by Chi-square test or Fisher's exact test, and *P* values less than 0.05 were considered significant. Statistical analysis was

performed using Stata version 10 (StataCorp, College Station, TX, USA). When necessary, *P* values were subjected to Bonferroni's correction for multiple comparisons. To determine whether genotype frequencies in the populations are compatible with Hardy–Weinberg equilibrium, Hardy–Weinberg exact tests were carried out using the program Arlequin version 3.11 (Excoffier et al. 2007). To assess pairwise LD between polymorphisms, we calculated Lewontin's *D'* and *r* square (*r*<sup>2</sup>) for polymorphisms by Haploview version 4.2 (Barrett et al. 2005). TB disease associated with genetic variations was assessed by odds ratios unadjusted or adjusted for sex, age at recruitment and its interaction using logistic models. Tendency of having resistant alleles in the order of age at diagnosis was also tested using a similar logistic model within the TB group. Difference in luciferase activity between the haplotype under consideration and the other haplotypes was assessed by Wilcoxon rank sum/Mann–Whitney *U* test.

## Results

### Microsatellite markers

Microsatellite marker *IFNGR2*-MS1 located in 5'-upstream region of *IFNGR2* showed significant association with TB even after Bonferroni's correction (Table 1) and the frequency of *IFNGR2*-MS1-325 allele was significantly lower in TB patients than in controls (Supplementary table 1). *IFNGR2*-MS2, the other microsatellite was located in intron 2 of *IFNGR2* and the frequency of *IFNGR2*-MS2-252 allele was also lower in TB patients than in controls (uncorrected *P* = 0.0024), but not significant after Bonferroni's correction. *IFNGR2*-MS1-325 allele and *IFNGR2*-MS2-252 allele were in LD (*D'* = 0.91, *r*<sup>2</sup> = 0.64).

### Screening of genetic polymorphisms in *IFNGR2*

Forty-eight control samples were subjected to PCR amplifications of promoter and seven exons of *IFNGR2* and their sequences were analyzed for possible polymorphisms. In the exonic sequences of *IFNGR2*, a non-synonymous SNP, rs9808753 was found in exon 2, and another SNP, rs1059293 was shown in 3'-untranslated region (UTR) of exon 7, while there were no SNPs in exon–intron boundaries. In the 5' region up to -850 bp of the translation initiation codon, three SNPs, rs8134145, rs8126756 and rs17882748 were also identified.

### Genotyping of selected SNPs around *IFNGR2*

Association of microsatellite markers of *IFNGR2* with TB prompted us to identify relevant SNPs that may show

**Table 1** Association results for microsatellite markers

Marker	Locus	No. of alleles (total)	No. of alleles (<5% grouped <sup>a</sup> )	<i>P</i> value <sup>b</sup> (2 × m)	Minimum <i>P</i> value <sup>b</sup> (2 × 2)	<i>P</i> value <sup>c</sup> Corrected	<i>P</i> value HWE
<i>IFNGR1</i> -MS1	6q23.3	14	7	0.419	0.0549	NS	0.4858
<i>IFNGR2</i> -MS1	21q22.11	8	5	0.016	0.0009	0.036	0.2762
<i>IFNGR2</i> -MS2		6	4	0.013	0.0024	NS	0.0326
<i>IL12RB1</i> -MS1	19p13.1	4	4	0.366	0.1600	NS	0.1606
<i>IL12RB2</i> -MS1	1p31.3-p31.2	12	6	0.155	0.0267	NS	0.7499
<i>IL12RB2</i> -MS2		6	4	0.540	0.2228	NS	0.7289
<i>STAT1</i> -MS1	2q32.2	13	5	0.563	0.3010	NS	0.0254
<i>STAT4</i> -MS1	2q32.2-q32.3	11	5	0.232	0.1046	NS	0.5243


NS not significant, HWE Hardy–Weinberg equilibrium

<sup>a</sup> Alleles with frequencies less than 5% were grouped

<sup>b</sup> Fisher's exact test

<sup>c</sup> Bonferroni's correction. 2 × 2 minimum *P* value was multiplied by the numbers of total alleles (40)

**Fig. 1** Association *P* values and pairwise LD of genotyped polymorphisms around *IFNGR2* region. **a** Association results for 32 SNPs in 273 patients (panel A) and 506 controls are shown. *P* values of microsatellite markers in 98 patients and 200 controls are also included. Positions of genes are shown on the top. **b** Pairwise LD ( $r^2$ ) between 32 SNPs and 2 microsatellite markers determined by the Haploview program is shown. In the calculation of pairwise LD, microsatellite alleles except for one showing the smallest *P* value were grouped, and the microsatellite locus was regarded as having only two alleles



further association. We genotyped 27 SNPs selected around *IFNGR2*, 3 SNPs in the 5' upstream region, a non-synonymous SNP in exon 2, and a 3'UTR SNP in exon 7 of *IFNGR2* in 273 TB patients (panel A) and 506 controls (Fig. 1, Supplementary table 2). The rs2834213 SNP in intron 2 and the rs1059293 SNP in 3'UTR were associated with TB ( $P = 0.0073$ , OR 0.69 95% confidence interval [CI] 0.52–0.91;  $P = 0.0088$ , OR 0.70 95% CI 0.54–0.92). These SNPs were in Hardy–Weinberg equilibrium in the control group. We confirmed that SNPs in other nearby genes were not associated with the disease (Supplementary table 2). As expected, the resistant G allele of rs2834213

and C allele of rs1059293 were both in LD with *IFNGR2*-MS1-325 allele and *IFNGR2*-MS2-252 allele (Supplementary Fig. 1). Particularly, the resistant G allele of rs2834213 in intron 2 was in high LD with *IFNGR2*-MS1-325 allele ( $D' = 0.94$ ,  $r^2 = 0.83$ ), that is located 1.9 kb upstream of the translation initiation codon.

Directly determined haplotypes consisting of three SNPs in the 5' GC-rich region of *IFNGR2*

In addition to single SNPs associated with the disease, we also characterized a set of SNPs in the 5' GC-rich region of



the gene, rs8134145, rs8126756 and rs17882748, since these three SNPs are closely located within 300 bp upstream of the transcription start site as discussed below, which may influence *IFNGR2* expression. When we directly determined haplotypes of three 5' SNPs by allele-specific sequencing in 273 patients and in 506 controls, three common haplotypes (CCC, ATC and ATT) accounted for 99.7% of chromosomes. The haplotype ATC was in high LD with the intron 2 SNP rs2834213 ( $D' = 0.97$ ,  $r^2 = 0.82$ ), and frequencies of the ATC haplotype were significantly lower in patients than in controls ( $P = 0.036$ , OR 0.76 95% CI 0.58–0.99). Haplotypes carrying SNPs in the entire *IFNGR2* region and their frequencies were estimated in 273 patients and in 506 controls. Consequently, the G allele of the intron 2 SNP rs2834213, the C allele of the 3'UTR SNP rs1059293 and the directly determined haplotype ATC, are uniquely contained in the same haplotype as shown in Supplementary table 3.

#### Transcription start site (TSS) of *IFNGR2*

In the public database, the aforementioned 5' SNPs, rs8134145, rs8126756, and rs17882748 are regarded as variants in 5' UTR, since TSS of the reference cDNA sequence (NM\_005534.3) is located at position –648 of the translation initiation codon. However, multiple TSS were actually reported in *IFNGR2*, the positions of which were distributed from the initiation codon to almost 990 bp upstream, presumably due to cell type differences (Rhee et al. 1996). For this reason, we determined the 5' ends by 5' RACE in our study. As a result, TSS obtained from all immune cell lines tested were 121 bp upstream of the initiation codon. Thus, the positions of the three SNPs were calculated as –295, –285 and –8 from the TSS, indicating that they are promoter variants in these cell types.

#### Association results of TB panel B

We selected the intron 2 SNP, rs2834213 as a representative SNP for the disease-resistant polymorphisms and genotyped 503 patients in TB panel B, which were compared with the original control subjects ( $N = 506$ ) in Table 2. The G allele of rs2834213 was significantly associated with TB in panel B ( $P = 0.0025$ , OR 0.71 95% CI 0.57–0.89). In a logistic model to assess possible confounders, adjusted odds ratios was compared with non-adjusted odds ratios for the G allele, which were hardly affected by sex, age at recruitment and its interaction term, indicating that the *IFNGR2* SNP remained significantly associated with TB in dominant and recessive models respectively ( $P = 0.016$  and  $P = 0.004$ ; table not shown).

Furthermore, we set up another logistic model to examine the relationship between having the TB-resistant

**Table 2** Association results of rs2834213 A/G SNP

Sample	Allele (frequency)		Genotype (%)			P value		OR (95% CI)	
	A	G	A/A	A/G	G/G	Allele	Genotype	Allele	Genotype
TB panel A	452 (0.837)	88 (0.163)	186 (68.9)	80 (29.6)	4 (1.5)	0.0073	0.047	0.69 (0.52–0.91)	0.73 (0.57–0.92)
TB panel B	838 (0.833)	168 (0.167)	347 (67.0)	144 (28.6)	12 (2.4)	0.0025	0.015	0.71 (0.57–0.89)	0.72 (0.56–0.95)
TB combined	1290 (0.834)	256 (0.166)	533 (69.0)	224 (29.0)	16 (2.1)	0.00054	0.0075	0.70 (0.57–0.86)	0.73 (0.57–0.92)
Controls	786 (0.780)	222 (0.220)	311 (61.7)	164 (32.5)	29 (5.8)				

TB tuberculosis, OR odds ratio, CI confidence interval

**Table 3** Tendency of having G allele (rs2834213) in the order of age strata at the time of diagnosis ( $N = 757$ )

Age at diagnosis (year)	GA or GG genotype (n/N)	(%)	Odds ratio per 10-year change* (95% CI)
16–25	35/124	28.2	0.88 (0.79–0.98)
26–35	43/171	25.1	
36–45	53/165	32.1	
46–55	54/171	31.6	
56–65	35/87	40.2	
65–	15/39	38.5	

\* In a logistic model, the trend of having the G allele was calculated as odds ratio when the patients are 10-years younger at the time of diagnosis ( $P = 0.019$ )

G alleles (as binary outcome) and age at diagnosis (as a continuous variable). In patients from panel A and B ( $n = 757$ ), the TB-resistant G allele was less frequently found, as the age at diagnosis was younger ( $P = 0.011$ ). Similarly, in the age-stratified analysis, when the patients are 10 years younger at the time of diagnosis, the odds ratio (OR) for having the G allele was 0.88 (95% CI, 0.79–0.98) and this trend remained significant ( $P = 0.019$ ) (Table 3).


#### Luciferase assay

We constructed plasmids containing 5' fragments in which only nucleotide sequences of the three promoter SNPs rs8134145, rs8126756, and rs17882748 are different and measured transcriptional activity of the three promoter segments (CCC, ATC, and ATT) in Jurkat human T-cell leukemia cells. Consequently, the resistant ATC haplotype had significantly higher transcriptional activity than CCC haplotype and ATT haplotype ( $P = 0.037$  respectively) by Mann–Whitney  $U$  test (Fig. 2).

#### Discussion

IFN- $\gamma$  plays a crucial role in host defense against intracellular pathogens mainly through activation of macrophages and regulation of Th1 cell response (Boehm et al. 1997). IL-12 released from dendritic cells and macrophages drives production of IFN- $\gamma$  via IL-12 receptors, IL12RB1 and IL12RB2, on Th1 cells and subsequent activation of STAT4. In turn, IFN- $\gamma$  binds to IFN- $\gamma$  receptors composed of IFNGR1 and IFNGR2 subunits and transduces STAT1 signals to target cells (Bach et al. 1997).

In this study, we first screened eight microsatellite markers within the genes encoding these Th1 cytokine receptors and signal transducers, and demonstrated that the *IFNGR2* marker alleles showed significant association with



**Fig. 2** Dual luciferase reporter assays. The ratios of Firefly luciferase activity (signal S) to Renilla luciferase activity (control C) are displayed using box and whisker plots. Three subcloned plasmids were prepared, and each subcloned plasmid was tested in triplicate and S/C values were averaged. The experiments were carried out twice independently. As a result, six independent S/C values were obtained for each haplotype. ATC haplotype showed significantly higher transcriptional activity than CCC haplotype and ATT haplotype (\*, \*\* $P = 0.037$ , respectively) by Mann–Whitney  $U$ -test. No significant difference was observed between CCC and ATT haplotypes (data not shown)

active TB. SNPs around the gene were analyzed and a strong disease association with the intron 2 SNP rs2834213, the 3'UTR SNP rs1059293 and the 5' promoter segment characterized by three SNPs was thus demonstrated. Possible influence of population substructure was kept to a minimum, since their ethnicity was Hanoi Vietnamese in which more than 99% were the Kinh people (Hoa et al. 2008).

To our knowledge, this is the first report of *IFNGR2* polymorphisms associated with TB. Intron 2 SNP, rs2834213 was most robustly associated with TB, but its biological importance is currently unclear. Indeed, it was not located near the splice sites (5,582 nucleotides downstream of splice donor site and 877 nucleotides upstream of splice acceptor site). A SNP in 3'UTR of exon 7 rs1059293 was in strong LD with the rs2834213 and also associated with TB, but it was 99 nucleotides upstream of polyadenylation signal. *IFNGR2* did not carry any non-synonymous SNP in high LD with rs2834213.

In an attempt to search functional polymorphism(s) in strong LD with the intron SNP (rs2834213) further, we identified the 300 bp promoter segment containing three SNPs. HapMap database does not have data of the three promoter SNPs, presumably due to high GC content that hinders high throughput genotyping method. The direct haplotyping revealed that it was also associated with the disease as well as the intron 2-SNP. Although we demonstrated that the promoter ATC haplotype showing an inverse disease association has high transcriptional activity in vitro and may confer resistance to TB, we could not

conclude which polymorphism around *IFNGR2* is primarily responsible for the disease until the functional roles of other SNPs showing more robust association are fully studied.

Among previous TB association studies with Th1-related genes, CC genotype at the -56 C/T SNP (rs2234711) of *IFNGR1* was repeatedly associated with TB in African populations (Cooke et al. 2006; Stein et al. 2007). In our study, *IFNGR1*-MS1-158 allele was in strong LD with -56 SNP (Tanaka et al. 2005), but this *IFNGR1* marker allele was not associated with TB. The lack of association is presumably because of insufficient power to detect weak genetic effects. Otherwise, it could be due to population-specific LD, when the true causative variant was not -56 SNP itself.

Experimental data have shown that *IFNGR2* is a key regulator for IFN- $\gamma$ -STAT1 signaling in T cells (Schroder et al. 2004; Regis et al. 2006). During the development of Th1 cells, *IFNGR2* transcription is reduced in the IFN- $\gamma$  rich condition and this reduction alleviates a potentially harmful anti-proliferative action of IFN- $\gamma$ -STAT1 signaling. However, *IFNGR2* expression is not completely suppressed, because temporary activation of STAT1 is still necessary for Th1 system. *IFNGR2* transcription is thus fine-tuned during the Th1 differentiation process. In the promoter region, the transcriptional activity of the resistant haplotype ATC was higher than the other two common haplotypes in the Jurkat T cell line at baseline levels. Although physiological modulation of *IFNGR2* expression is not easily simulated in a single cell-type model, this segment may have a potential to influence Th1 function through *IFNGR2* regulation.

In this study, another interesting finding is that the resistant allele tend to be less frequently observed in younger patients at the time of diagnosis, a surrogate for age at onset in new patients. This effect was moderate but significant. The allele frequency in older age at diagnosis nearly reached the level of the control population. It is likely that the elderly kept latent infection of *M. tuberculosis* for long years, and the age-associated decline in immune response caused development of active TB, while the younger patients developed active TB soon after initial infection (Tufariello et al. 2003). In intermediate or low burden countries, there are more elderly patients and the effect of the resistant allele of *IFNGR2* may be smaller.

Moreover, in African countries with high rates of TB and HIV co-infection, HIV is the strongest risk factor for TB development (Reid et al. 2006). By contrast, the proportion of HIV-positive TB patients is only 8.8% in the Vietnamese TB panel B and 1.4% in TB panel A, therefore possible effect of the resistant allele on HIV infection could not be determined in this study. In the

previous reports, other polymorphisms of *IFNGR2* were associated with liver fibrosis of chronic hepatitis C virus infection and with viremia of hepatitis B virus infection (Nalpas et al. 2010; Huang et al. 2011). Because IFN- $\gamma$  is a key cytokine for the control of infectious diseases, association of *IFNGR2* polymorphisms with HIV infection needs be clarified.

One limitation in our study is a single control panel of the Vietnamese population. Results of the first case-control set were only partially confirmed because of incomplete independence of the two study sets, though sample size itself was not small. Another limitation is that our control panel may include asymptomatic individuals with latent TB infection, because performing tuberculin testing is not common in Vietnam. Considering two-stage process of infection with the pathogen and progression to disease, we cannot directly specify which stage of TB was more affected by *IFNGR2* in our study population. Future use of interferon gamma release assays to detect latent infection of *M. tuberculosis* in this field might be helpful to arrive at a solution (Pai et al. 2008). Because of the complexity of LD structure and the age-dependent effect as regards these variations, carefully conducted studies should be undertaken to reproduce our results in other populations. Validation studies by re-sequencing are also warranted. In non-Asian populations, however, the LD of rs2834213 does not appear to reach the promoter region of *IFNGR2* (data not shown), indicating that the functional promoter haplotype may not be easily found in disease marker association studies by the conventional tag SNP-based approach in other populations.

We conclude that the polymorphisms of *IFNGR2* may confer resistance to TB in Vietnam. It appeared to be different depending on age at diagnosis. Further functional studies are needed to elucidate the genetic susceptibility to TB, fully considering complicated immune process regarding early or late onset of the disease.

**Ethical standards** We declare that these experiments comply with the current laws of Japan and Vietnam.

**Acknowledgments** We thank Izumi Matsumoto, Masako Okochi and Keiko Wakabayashi for their technical assistance. The authors thank Kazuko Tanabe D.V.M. and Mr. John Crosskey for their critical reading of this manuscript. This work was partly supported by a grant from the Program of Japan Initiative for Global Research Network on Infectious Diseases (J-GRID), Ministry of Education, Culture, Sports, Science and Technology, Japan.

**Conflict of interest** The authors declare that they have no conflict of interest.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

## References

- Bach EA, Aguet M, Schreiber RD (1997) The IFN gamma receptor: a paradigm for cytokine receptor signaling. *Annu Rev Immunol* 15:563–591
- Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics* 21:263–265
- Boehm U, Klamp T, Groot M, Howard JC (1997) Cellular responses to interferon-gamma. *Annu Rev Immunol* 15:749–795
- Cooke GS, Campbell SJ, Sillah J, Gustafson P, Bah B, Sirugo G, Bennett S, McAdam KP, Sow O, Lienhardt C, Hill AV (2006) Polymorphism within the interferon-gamma/receptor complex is associated with pulmonary tuberculosis. *Am J Respir Crit Care Med* 174:339–343
- Cooper AM (2009) T cells in mycobacterial infection and disease. *Curr Opin Immunol* 21:378–384
- Excoffier L, Laval G, Schneider S (2007) Arlequin (version 3.0): an integrated software package for population genetics data analysis. *Evol Bioinform Online* 1:47–50
- Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C (2003) Tuberculosis. *Lancet* 362:887–899
- Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adegemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D (2002) The structure of haplotype blocks in the human genome. *Science* 296:2225–2229
- Hang NT, Lien LT, Kobayashi N, Shimbo T, Sakurada S, Thuong PH, le Hong T, Tam do B, Hijikata M, Matsushita I, Hung NV, Higuchi K, Harada N, Keicho N (2011) Analysis of factors lowering sensitivity of interferon- $\gamma$  release assay for tuberculosis. *PLoS One* 6:e23806
- Hoang BK, Hang NT, Kashiwase K, Ohashi J, Lien LT, Horie T, Shojima J, Hijikata M, Sakurada S, Satake M, Tokunaga K, Sasazuki T, Keicho N (2008) HLA-A, -B, -C, -DRB1 and -DQB1 alleles and haplotypes in the Kinh population in Vietnam. *Tissue Antigens* 71:127–134
- Horie T, Lien LT, Tuan LA, Tuan PL, Sakurada S, Yanai H, Keicho N, Nakata K (2007) A survey of tuberculosis prevalence in Hanoi, Vietnam. *Int J Tuberc Lung Dis* 11:562–566
- Huang HH, Shih WL, Li YH, Wu CF, Chen PJ, Lin CL, Liu CJ, Liaw YF, Lin SM, Lee SD, Yu MW (2011) Hepatitis B viraemia: its heritability and association with common genetic variation in the interferon gamma signalling pathway. *Gut* 60:99–107
- International HapMap Consortium (2005) A haplotype map of the human genome. *Nature* 437:1299–1320
- Lin PL, Flynn JL (2010) Understanding latent tuberculosis: a moving target. *J Immunol* 185:15–22
- Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ (2006) Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. *Lancet* 367:1747–1757
- Möller M, de Wit E, Hoal EG (2010a) Past, present and future directions in human genetic susceptibility to tuberculosis. *FEMS Immunol Med Microbiol* 58:3–26
- Möller M, Nebel A, van Helden PD, Schreiber S, Hoal EG (2010b) Analysis of eight genes modulating interferon gamma and human genetic susceptibility to tuberculosis: a case-control association study. *BMC Infect Dis* 10:154
- Nalpas B, Lavialle-Meziani R, Plancoulaine S, Jouanguy E, Nalpas A, Munteanu M, Charlotte F, Ranque B, Patin E, Heath S, Fontaine H, Vallet-Pichard A, Pontoire D, Bourlière M, Casanova JL, Lathrop M, Bréchet C, Poynard T, Matsuda F, Pol S, Abel L (2010) Interferon gamma receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection. *Gut* 59:1120–1126
- Nishida N, Tanabe T, Takasu M, Suyama A, Tokunaga K (2007) Further development of multiplex single nucleotide polymorphism typing method, the DigiTag2 assay. *Anal Biochem* 364:78–85
- Pai M, Zwerling A, Menzies D (2008) Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. *Ann Intern Med* 149:177–184
- Panteleeff DD, John G, Nduati R, Mbori-Ngacha D, Richardson B, Kreiss J, Overbaugh J (1999) Rapid method for screening dried blood samples on filter paper for human immunodeficiency virus type 1 DNA. *J Clin Microbiol* 37:350–353
- Regis G, Conti L, Boselli D, Novelli F (2006) IFN $\gamma$ STAT1 trafficking tunes IFN $\gamma$ -STAT1 signaling in T lymphocytes. *Trends Immunol* 27:96–101
- Reid A, Scano F, Getahun H, Williams B, Dye C, Nunn P, De Cock KM, Hankins C, Miller B, Castro KG, Raviglione MC (2006) Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. *Lancet Infect Dis* 6:483–495
- Rhee S, Ebersperger C, Dembic Z, Pestka S (1996) The structure of the gene for the second chain of the human interferon-gamma receptor. *J Biol Chem* 271:28947–28952
- Russell DG (2007) Who puts the tubercle in tuberculosis? *Nat Rev Microbiol* 5:39–47
- Schroder K, Hertzog PJ, Ravasi T, Hume DA (2004) Interferon-gamma: an overview of signals, mechanisms and functions. *J Leukoc Biol* 75:163–189
- Schwende H, Fitzke E, Ambs P, Dieter P (1996) Differences in the state of differentiation of THP-1 cells induced by phorbol ester and 1, 25-dihydroxyvitamin D3. *J Leukoc Biol* 59:555–561
- Stein CM, Zalwango S, Chiunda AB, Millard C, Leontiev DV, Horvath AL, Cartier KC, Chervenak K, Boom WH, Elston RC, Mugerwa RD, Whalen CC, Iyengar SK (2007) Linkage and association analysis of candidate genes for TB and TNF $\alpha$  cytokine expression: evidence for association with IFNGR1, IL-10, and TNF receptor 1 genes. *Hum Genet* 121:663–673
- Tanaka G, Matsushita I, Ohashi J, Tsuchiya N, Ikushima S, Oritsu M, Hijikata M, Nagata T, Yamamoto K, Tokunaga K, Keicho N (2005) Evaluation of microsatellite markers in association studies: a search for an immune-related susceptibility gene in sarcoidosis. *Immunogenetics* 56:861–870
- Tufariello JM, Chan J, Flynn JL (2003) Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. *Lancet Infect Dis* 3:578–590
- World Health Organization (2010) Global tuberculosis control 2010. WHO website [http://www.who.int/tb/publications/global\\_report/2010/](http://www.who.int/tb/publications/global_report/2010/)
- Zhang SY, Boisson-Dupuis S, Chappier A, Yang K, Bustamante J, Puel A, Picard C, Abel L, Jouanguy E, Casanova JL (2008) Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN- $\alpha$ /beta, IFN- $\gamma$ , and IFN- $\lambda$  in host defense. *Immunol Rev* 226:29–40

# Circulating Levels of Adiponectin, Leptin, Fetuin-A and Retinol-Binding Protein in Patients with Tuberculosis: Markers of Metabolism and Inflammation

Naoto Keicho<sup>1\*</sup>, Ikumi Matsushita<sup>1</sup>, Takahiro Tanaka<sup>1</sup>, Takuro Shimbo<sup>2</sup>, Nguyen Thi Le Hang<sup>3</sup>, Shinsaku Sakurada<sup>1</sup>, Nobuyuki Kobayashi<sup>4</sup>, Minako Hijikata<sup>1</sup>, Pham Huu Thuong<sup>5</sup>, Luu Thi Lien<sup>5</sup>

**1** Department of Respiratory Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan, **2** Department of Clinical Research and Informatics, International Clinical Research Center, National Center for Global Health and Medicine, Tokyo, Japan, **3** National Center for Global Health and Medicine–Bach Mai Hospital Medical Collaboration Center, Hanoi, Viet Nam, **4** Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan, **5** Hanoi Lung Hospital, Hanoi, Viet Nam

## Abstract

**Background:** Wasting is known as a prominent feature of tuberculosis (TB). To monitor the disease state, markers of metabolism and inflammation are potentially useful. We thus analyzed two major adipokines, adiponectin and leptin, and two other metabolic markers, fetuin-A and retinol-binding protein 4 (RBP4).

**Methods:** The plasma levels of these markers were measured using enzyme-linked immunosorbent assays in 84 apparently healthy individuals (=no-symptom group) and 46 patients with active pulmonary TB around the time of treatment, including at the midpoint evaluation (=active-disease group) and compared them with body mass index (BMI), C-reactive protein (CRP), chest radiographs and TB-antigen specific response by interferon- $\gamma$  release assay (IGRA).

**Results:** In the no-symptom group, adiponectin and leptin showed negative and positive correlation with BMI respectively. In the active-disease group, at the time of diagnosis, leptin, fetuin-A and RBP4 levels were lower than in the no-symptom group [adjusted means 2.01 versus 4.50 ng/ml,  $P < 0.0001$ ; 185.58 versus 252.27  $\mu\text{g/ml}$ ,  $P < 0.0001$ ; 23.88 versus 43.79  $\mu\text{g/ml}$ ,  $P < 0.0001$ , respectively]. High adiponectin and low leptin levels were associated with large infiltrates on chest radiographs even after adjustment for BMI and other covariates ( $P = 0.0033$  and  $P = 0.0020$ ). During treatment, adiponectin levels increased further and then decreased. Leptin levels remained low. Initial low levels of fetuin-A and RBP4 almost returned to the normal reference range in concert with reduced CRP.

**Conclusions:** Our data and recent literature suggest that low fat store and underlying inflammation may regulate these metabolic markers in TB in a different way. Decreased leptin, increased adiponectin, or this ratio may be a promising marker for severity of the disease independent of BMI. We should further investigate pathological roles of the balance between these adipokines.

**Citation:** Keicho N, Matsushita I, Tanaka T, Shimbo T, Hang NTL, et al. (2012) Circulating Levels of Adiponectin, Leptin, Fetuin-A and Retinol-Binding Protein in Patients with Tuberculosis: Markers of Metabolism and Inflammation. PLoS ONE 7(6): e38703. doi:10.1371/journal.pone.0038703

**Editor:** Pere-Joan Cardona, Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Universitat Autònoma de Barcelona, CIBERES, Spain

**Received:** January 19, 2012; **Accepted:** May 9, 2012; **Published:** June 7, 2012

**Copyright:** © 2012 Keicho et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported by a grant from the Program of Japan Initiative for Global Research Network on Infectious Diseases, MEXT, Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

\* E-mail: nkeicho-ky@umin.ac.jp

## Introduction

Tuberculosis (TB) is a major infectious cause of death around the world, with most of the 1.5 million deaths per year attributable to the disease occurring in developing countries. Negative energy balance in chronic inflammation has been recognized as a prominent feature of TB and one of the major obstacles to manage the patients [1,2]. Recent emergence of drug resistant TB is assumed to be driven by poorly implemented drug regimens, but malnutrition as well as HIV co-infection might worsen the condition: Inflammatory responses evoked by infection increase the demand for anabolic energy, leading to a synergistic vicious circle and further deterioration of the clinical condition [3].

It is generally believed that undernourishment diminishes protective immunity against *Mycobacterium tuberculosis*. [4]. A series of animal experiments, particularly aerosol-infected guinea pig models have demonstrated that chronic protein-energy malnutrition reduces secretion of T-helper 1 (Th1) cytokines [5]. It is rapidly reversed with alimentary supplement, indicating a pivotal role of nutrition, although it remains unclear what the optimal nutritional interventions are for improving the human disease in an effective manner [4].

On the other hand, in many countries today, rapid industrialization and urbanization are accompanied by changing patterns of diet and physical activity and this results in over-nutrition [6]. Consequently, a combination of these two unfavor-

**Table 1.** Characteristics of study population.

	no-symptom group (N = 84)	active-disease group (N = 46)	P values
Male/Female (n)	41/43	42/4	<0.0001
Age (year)*	40.0 (28.1–48.6)	47.2 (34.7–55.0)	0.0064
BMI (kg/m <sup>2</sup> )*	21.8 (20.0–23.7)	18.3 (17.1–19.5)	<0.0001
BCG history (yes/no/unknown)	33/28/23	10/3/33	<0.0001
positive/negative results of IGRA (n)	55/29	41/4**	0.0015

\*Median and 25-to-75 percentiles in parenthesis are shown.

\*\*One indeterminate case is not shown here.

doi:10.1371/journal.pone.0038703.t001

able conditions, a slow decline of infectious diseases associated with undernutrition and a rapid increase in obesity and diabetes are a serious double burden to public health and clinical medicine in resource limited settings [7].

Mainly in studies carried out in industrialized countries, fat-cell-derived hormones/cytokines designated as adipokines and relevant mediators have been investigated extensively and proposed as markers of obesity and diabetes [8]. Of these adipokines, adiponectin is a unique insulin sensitizer with atheroprotective role [9,10]. Plasma levels of adiponectin are inversely correlated with body weight and visceral fat mass [11,12]. Leptin is another major adipokine in proportion to fat stores [13,14] and one of the key mediators of energy metabolism [2]. Even mild weight loss induced by dietary restriction is known to reduce leptin levels [11]. These markers supposedly shift towards the opposite in lean patients with wasting diseases. However, the significance of these metabolic markers in chronic infectious diseases like TB has not been fully understood [2].

We have recently conducted a proteomic research and demonstrated that plasma levels of fetuin-A and retinol-binding protein 4 (RBP4), also closely linked to the metabolic and inflammatory state, were significantly lower in patients with active pulmonary TB than in control subjects [15]. Fetuin-A, also known as  $\alpha$ 2-Heremans-Schmid glycoprotein, is an abundant plasma

component of hepatic origin [16] and a negative regulator of insulin signaling [17,18]. Elevation of plasma fetuin-A is strongly associated with atherogenic lipid profile as well as fatty liver in obese patients [18]. Lipid components in the liver presumably upregulate fetuin-A expression, which may in turn repress adiponectin and impair adipocyte function [19,20]. Fetuin-A is also downregulated in acute inflammation as a negative acute-phase protein [21]. RBP4, synthesized in the liver and adipose tissue, has recently been identified as another adipokine involved in the development of insulin resistance [22]. In humans, similar to leptin, circulating RBP4 levels are high in obesity and decreased after calorie-restriction induced weight loss [11,23]. RBP4 is also known as a specific transporter protein for retinol (vitamin A) and can be used to assess the short-term fluctuation of nutritional states as a rapid turnover protein [24].

Alteration of the circulating levels of these markers should be investigated in TB, since they are expected to provide a basis of a critical link among nutritional status, metabolism and immunity of the disease, and hopefully to consider efficient nutritional interventions. In the present study, we thus measured circulating adiponectin and leptin in addition to fetuin-A and RBP4 levels in patients with active pulmonary TB versus apparently healthy individuals and compared the levels with body mass index (BMI), a simple estimate of adiposity [25] and C-reactive protein (CRP),

**Table 2.** Correlation of tested marker levels with BMI, CRP and IGRA values in each of the no-symptom and active-disease groups.

Variable	no-symptom group (N = 84)			active-disease group (N = 46)		
	Pearson's <i>r</i> (P values) <sup>a</sup>			Pearson's <i>r</i> (P values) <sup>a</sup>		
	by BMI (kg/m <sup>2</sup> )	by CRP ( $\mu$ g/ml)	by IFN- $\gamma$ (IU/ml) <sup>b</sup>	by BMI (kg/m <sup>2</sup> )	by CRP ( $\mu$ g/ml)	by IFN- $\gamma$ (IU/ml) <sup>b</sup>
Adiponectin ( $\mu$ g/ml)	-0.4530 (<0.0001)*	-0.2892 (0.0076)	-0.2254 (0.0393)	-0.4421 (0.0021)	0.1477 (0.3274)	-0.1092 (0.4700)
Leptin (ng/ml)	0.4518 (<0.0001)*	0.1694 (0.1234)	0.1179 (0.2855)	0.2771 (0.0623)	-0.0918 (0.5442)	0.3568 (0.0149)
Leptin/adiponectin ratio	0.5820 (<0.0001)*	0.2793 (0.0101)	0.2067 (0.0592)	0.4901 (0.0005)*	-0.1633 (0.2783)	0.2804 (0.0591)
Fetuin-A ( $\mu$ g/ml)	0.0309 (0.7805)	0.0415 (0.7079)	0.0322 (0.7714)	0.1243 (0.4105)	-0.1833 (0.2226)	0.2402 (0.1078)
RBP4 ( $\mu$ g/ml)	0.1605 (0.1447)	-0.0213 (0.8475)	0.0716 (0.5173)	0.1535 (0.3085)	-0.3018 (0.0415)	-0.0916 (0.5448)

<sup>a</sup>Pearson's correlation coefficients with P values were calculated. Plasma concentrations were analyzed after logarithmic transformation.

<sup>b</sup>TB-antigen stimulated IFN- $\gamma$  response

\*Statistically significant when the significance level is set as  $P < 0.002$  based on the Bonferroni correction.

doi:10.1371/journal.pone.0038703.t002

**Table 3.** BMI, CRP and tested marker levels in IGRA-positive and -negative subgroups in the no-symptom group.

marker	IGRA-negative (N = 29)		IGRA-positive (N = 55)		P values (ANCOVA)
	adjusted mean <sup>a</sup>	(95%CI)	adjusted mean <sup>a</sup>	(95%CI)	
BMI (kg/m <sup>2</sup> )	21.52	(20.58–22.46)	21.48	(20.74–22.22)	0.9392
CRP (µg/ml)	1.12	(0.60–2.08)	1.30	(0.80–2.12)	0.6663
Adiponectin (µg/ml)	7.19	(5.67–9.11)	6.39	(5.30–7.70)	0.3792
Leptin (ng/ml)	4.50	(3.34–6.05)	4.38	(3.47–5.54)	0.8783
Leptin/adiponectin ratio	0.63	(0.40–0.97)	0.69	(0.49–0.97)	0.7080
Fetuin-A (µg/ml)	234.22	(212.40–258.29)	263.88	(244.26–285.06)	0.0333
RBP4 (µg/ml)	39.64	(32.28–48.69)	42.88	(36.45–50.43)	0.4997

<sup>a</sup>Estimated means of plasma concentrations were compared after logarithmic transformation, being adjusted for gender and age as covariates. The data shown are transformed back to the original unit.

No P values were statistically significant when the significance level is set as  $P < 0.007$  based on the Bonferroni correction.

doi:10.1371/journal.pone.0038703.t003

a representative positive acute phase protein [26]. We further characterized their relationship with disease severity and alterations during the course of treatment.

## Methods

### Study design

We randomly selected and used plasma samples and demographic information in 46 patients with active pulmonary TB (= active-disease group) without treatment history as a biomarker sub-study of a large cohort study [27]. All patients entered the study from July 2007 to March 2009. Diagnosis of active pulmonary TB was made clinically and radiologically and confirmed bacteriologically in Hanoi Lung Hospital. A sputum smear test showed positive results in all of the patients in the active disease group and all of them completed anti-TB treatment following the national standard regimen, 2 months of streptomycin, isoniazid, rifampicin, and pyrazinamide followed by 6 months of isoniazid and ethambutol (2SHRZ/6HE).

Chest radiographs were taken at the time of diagnosis and interpreted by two readers independently in a blind manner. The presence of cavitary lesions and the number of lung zones (zero to six corresponding to the upper, middle, and lower fields on the

right and left sides of the lung) affected by infiltrates were recorded [28]. HIV status was examined before starting anti-TB treatment. The proportion of HIV co-infection is less than 10% in this study area and those with HIV positive were excluded from the drawing up of this sub-study.

As a reference, we also measured plasma samples derived from 84 apparently healthy men and women who may have chances of direct or indirect contacts with TB patients as health care staff (= no-symptom group). All participants were tested for TB-antigen specific interferon- $\gamma$  response by the commercially available enzyme-linked immunosorbent assay (ELISA)-based interferon- $\gamma$  release assay (IGRA), QuantiFERON-TB Gold In-Tube™ (Cellestis, Victoria, Australia). In the no-symptom group, IGRA-positive individuals suspected of latent TB infection were recommended to take chest radiography and to confirm there were no active pulmonary lesions. Subsequently a chance of receiving isoniazid prophylactic therapy was given. The protocol was approved by ethical committees of the Ministry of Health, Viet Nam and National Center for Global Health and Medicine, Japan respectively and written informed consent was obtained from each participant.

**Table 4.** BMI, CRP and tested marker levels in the no-symptom and active-disease groups after adjustment for gender and age.

marker	no-symptom group (N = 84)		active-disease group (N = 46)		P values (ANCOVA)
	adjusted mean <sup>a</sup>	(95%CI)	adjusted mean <sup>a</sup>	(95%CI)	
BMI (kg/m <sup>2</sup> )	21.68	(21.06–22.30)	17.65	(16.66–18.65)	<0.0001*
CRP (µg/ml)	1.22	(0.86–1.74)	36.88	(20.94–64.94)	<0.0001*
Adiponectin (µg/ml)	6.82	(5.73–8.12)	9.29	(7.02–12.30)	0.0136
Leptin (ng/ml)	4.50	(3.78–5.35)	2.01	(1.52–2.66)	<0.0001*
Leptin/adiponectin ratio	0.66	(0.50–0.88)	0.22	(0.14–0.34)	<0.0001*
Fetuin-A (µg/ml)	252.27	(234.55–271.33)	185.58	(165.07–208.64)	<0.0001*
RBP4 (µg/ml)	43.79	(38.09–50.34)	23.88	(19.08–29.88)	<0.0001*

<sup>a</sup>Estimated means of plasma concentrations were compared after logarithmic transformation, being adjusted for gender and age as covariates. The data shown are transformed back to the original unit.

\*Statistically significant when the significance level is set as  $P < 0.007$  based on the Bonferroni correction.

doi:10.1371/journal.pone.0038703.t004

**Table 5.** CRP and tested marker levels in the no-symptom and active-disease groups after adjustment for gender, age and BMI.

marker	no-symptom group (N = 84)		active-disease group (N = 46)		P values (ANCOVA)
	adjusted mean <sup>a</sup>	(95%CI)	adjusted mean <sup>a</sup>	(95%CI)	
CRP (µg/ml)	1.11	(0.77–1.60)	47.80	(25.36–90.09)	<0.0001*
Adiponectin (µg/ml)	7.80	(6.63–9.19)	6.39	(4.81–8.49)	0.1671
Leptin (ng/ml)	3.77	(3.26–4.37)	3.28	(2.54–4.24)	0.2790
Leptin/adiponectin ratio	0.48	(0.38–0.61)	0.51	(0.35–0.76)	0.7704
Fetuin-A (µg/ml)	248.04	(229.95–267.57)	194.46	(170.48–221.80)	0.0004*
RBP4 (µg/ml)	42.90	(37.08–49.63)	25.27	(19.62–32.55)	0.0001*

<sup>a</sup>Estimated means of plasma concentrations were compared after logarithmic transformation, being adjusted for gender, age and BMI as covariates. The data shown are transformed back to the original unit.

\*Statistically significant when the significance level is set as  $P < 0.008$  based on the Bonferroni correction.

doi:10.1371/journal.pone.0038703.t005

### Measurements of markers of metabolism and inflammation

Immediately after making the diagnosis of active TB disease, heparinized blood samples were drawn for IGRA before starting anti-TB treatment (0 month) and the remaining plasma without mixing any stimulants was reserved in a  $-80^{\circ}\text{C}$  freezer until measurement. Samples were collected twice again, after the initial phase of treatment (2 months) and at the end of treatment (7 months) in the active disease group. This study was originally intended to identify a variety of biomarkers associated with TB phenotypes [15] and the participants were not obliged to keep fasting. The blood was collected in the daytime between 8 am and 4 pm at the outpatient clinic to avoid interference in dosing schedule of anti-TB drugs.

The AssayMax Human C-Reactive Protein ELISA kit was used for detection of human c-reactive protein (CRP) in plasma (Assaypro LLC, St. Charles, MO, USA). The minimum detectable dose was less than 0.25 ng/ml. The Quantikine<sup>®</sup> Human Total Adiponectin/Acrp30 Immunoassay kit was used to detect total (low, middle and high molecular weight) human adiponectin in plasma (R&D Systems, Inc.; Minneapolis, MN, USA). The mean

minimum detectable dose was 0.246 ng/ml. The Quantikine<sup>®</sup> Human Leptin Immunoassay kit was used to detect human leptin in plasma (R&D Systems, Inc.). The mean minimum detectable dose was 7.8 pg/ml. The AHSG ELISA kit was used to detect fetuin-A in plasma (BioVendor Laboratory Medicine Inc.; Modrice, Czech Republic). The detection limit was 0.35 ng/ml. A competitive ELISA for quantitative determination of RBP4 in human plasma was also applied (AdipoGen Inc.; Seoul, Korea) and the detection limit was 1 ng/ml. All were performed according to the manufacturer's instructions. Differences in measured concentrations between EDTA plasma samples as reference and these heparin samples were within a range of variation generally accepted in ELISA (coefficient of variance <15%) (data not shown).

### Statistical analysis

Plasma protein levels were served for subsequent statistical analysis after logarithmic transformation of the measurements to minimize distortion of the data distribution. Means of demographic data between two groups were compared by analysis of variance (ANOVA) after testing for equal variances and

**Table 6.** BMI, CRP and tested marker levels in patients with small and large infiltrates on chest radiographs after adjustment for gender and age.

marker	small infiltrates <sup>a</sup> (N = 22)		large infiltrates <sup>a</sup> (N = 23)		P values (ANCOVA)
	adjusted mean <sup>b</sup>	(95%CI)	adjusted mean <sup>b</sup>	(95%CI)	
BMI (kg/m <sup>2</sup> )	18.73	(16.74–20.71)	18.11	(15.95–20.27)	0.3065
CRP (µg/ml)	26.14	(12.63–54.10)	35.92	(16.29–79.21)	0.1520
Adiponectin (µg/ml)	10.28	(5.38–19.66)	18.83	(9.31–38.11)	0.0033*
Leptin (ng/ml)	2.42	(1.64–3.57)	1.65	(1.08–2.52)	0.0020*
Leptin/adiponectin ratio	0.24	(0.11–0.52)	0.09	(0.04–0.21)	0.0002*
Fetuin-A (µg/ml)	201.97	(149.87–272.18)	184.68	(133.52–255.46)	0.3222
RBP4 (µg/ml)	36.14	(21.76–60.03)	31.56	(18.17–54.79)	0.3770
IFN- $\gamma$ (IU/ml) <sup>c</sup>	11.04	(2.13–57.16)	5.80	(0.97–34.82)	0.2039

<sup>a</sup>Small infiltrates = less than 3 of 6 zones in the lung affected, large infiltrates = 3 or more than 3 of 6 zones affected

<sup>b</sup>Estimated means of plasma concentrations were compared after logarithmic transformation, being adjusted for gender and age as covariates. The data shown are transformed back to the original unit.

<sup>c</sup>TB-antigen stimulated IFN- $\gamma$  response

\*Statistically significant when the significance level is set as  $P < 0.006$  based on the Bonferroni correction.

doi:10.1371/journal.pone.0038703.t006



**Table 7.** CRP and tested marker levels in patients with small and large infiltrates on chest radiographs after adjustment for gender, age and BMI.

marker	small infiltrates <sup>a</sup> (N=22)		large infiltrates <sup>a</sup> (N=23)		P values (ANCOVA)
	adjusted mean <sup>b</sup>	(95%CI)	adjusted mean <sup>b</sup>	(95%CI)	
CRP (µg/ml)	26.59	(12.78–55.28)	35.50	(16.02–78.63)	0.1991
Adiponectin (µg/ml)	10.84	(6.01–19.53)	18.15	(9.57–34.40)	0.0061*
Leptin (ng/ml)	2.37	(1.63–3.47)	1.67	(1.11–2.52)	0.0040*
Leptin/adiponectin ratio	0.22	(0.11–0.44)	0.09	(0.04–0.20)	0.0002*
Fetuin-A (µg/ml)	200.77	(148.59–271.28)	185.46	(133.74–257.18)	0.3886
RBP4 (µg/ml)	35.69	(21.43–59.46)	31.83	(18.29–55.42)	0.4626
IFN-γ (IU/ml) <sup>c</sup>	11.41	(2.17–59.90)	5.68	(0.94–34.53)	0.1760

<sup>a</sup>Small infiltrates = less than 3 of 6 zones in the lung affected, large infiltrates = 3 or more than 3 of 6 zones affected

<sup>b</sup>Estimated means of plasma concentrations were compared after logarithmic transformation, being adjusted for gender, age and BMI as covariates. The data shown are transformed back to the original unit.


<sup>c</sup>TB-antigen stimulated IFN-γ response

\*Statistically significant when the significance level is set as  $P < 0.007$  based on the Bonferroni correction.

doi:10.1371/journal.pone.0038703.t007

proportions between two groups were compared by the chi-squared test. Since it is well known that levels of adipokines such as leptin are influenced by gender and age, measurements of protein markers in any two groups were compared by analysis of covariance (ANCOVA) to allow for the covariates. The relationship between markers and other parameters were assessed by Pearson's correlation coefficients. Overall alterations of the measurements at three time points were initially analyzed by repeated-measures ANOVA and only when statistically significant, post-hoc comparisons were proceeded to: Difference of values between two time points was assessed by the paired-T test, under

normal approximation based on the central limit theorem.  $P$  values  $< 0.05$  were considered to be statistically significant in general. When the Bonferroni correction was applied, however, a level of statistical significance was set as  $0.05/n$  ( $n$  = the number of comparisons). Statistical analysis was performed using Stata version 11 (StataCorp, College Station, TX, USA).



**Figure 1.** CRP and tested marker levels in patients with active TB before (0 month), during (2 months) and at the end (7 months) of anti-TB treatment (N = 46). Vertical bars with diamonds on the left side (M and F) indicate reference values, means  $\pm$  SEM of the values in men (N = 41) and women (N = 43) of the no-symptom group. A horizontal bar indicates the grand mean of the values in each condition. \* indicates  $P < 0.05$  by paired comparison between 0 month and 2 months. When significant, 2 months and 7 months were also compared.

doi:10.1371/journal.pone.0038703.g001

## Results

### Characteristics of study population

The no-symptom group consisted of 84 apparently healthy individuals, whose blood samples were used to obtain the standard values of markers in the study population. This group includes an approximately equal number of men and women with median age of 40, and more than half of the individuals had latent TB infection diagnosed by the IGRA method (Table 1). The active-disease group members were 46 patients with smear-positive active pulmonary TB. The majority of the patients were male with low body mass index ( $BMI < 18.5 \text{ kg/m}^2$ ) and the median age was 47, slightly older than in the non-symptom group.

### Correlation of adiponectin, leptin, fetuin-A and RBP4 levels with BMI, CRP and IGRA values in the no-symptom and active-disease groups

Correlation coefficients ( $r$ ) were calculated in the no-symptom and active-disease groups respectively (Table 2). Adiponectin and leptin showed negative and positive correlations with BMI respectively in the no-symptom group ( $r = -0.4530$ ,  $P < 0.0001$ ;  $r = 0.4518$ ,  $P < 0.0001$ ). Leptin/adiponectin ratio showed a positive correlation with BMI in the active-disease group ( $r = 0.4901$ ,  $P = 0.0005$ ) as well as in the no-symptom group ( $r = 0.5820$ ,  $P < 0.0001$ ). These correlations were statistically significant even after Bonferroni correction for multiple comparisons. The other possible correlations including a pair of leptin and TB-antigen stimulated IFN- $\gamma$  response did not reach significant levels in this study, when Bonferroni correction was applied.

### Pairwise correlations between four tested markers

Pairwise correlation coefficients ( $r$ ) between four tested metabolic markers were further calculated in the no-symptom and active-disease groups respectively (Table S1). A significant correlation was found only between fetuin-A and RBP4 levels ( $r = 0.4007$ ,  $P = 0.0058$ ) in the active disease group.

### Adiponectin, leptin, fetuin-A and RBP4 levels with IGRA-positive and -negative subgroups in the no-symptom group

IGRA-positive values higher than the cutoff value, 0.35 IU/ml are regarded as latent TB infection after active disease is ruled out. We thus categorized the no-symptom group into IGRA-positive and -negative subgroups and compared plasma concentrations of the above markers. However, none of the marker levels including fetuin-A were significantly different between IGRA-positive and -negative subgroups after adjustment for gender and age, when considering the number of comparisons (Table 3).

### Adiponectin, leptin, fetuin-A and RBP4 levels in the no-symptom and active-disease groups

The active-disease group had significantly low BMI and very high CRP levels at the time of diagnosis, when assessed by using ANCOVA with adjusted means (Table 4). In the disease group, leptin, leptin/adiponectin ratio, fetuin-A and RBP4 levels were remarkably lower than in the no-symptom group ( $P < 0.0001$  respectively) after adjustment for gender and age and these differences were statistically significant even after Bonferroni correction (Table 4).

Since BMI was strongly correlated with some of the adipokine values as shown in Table 2, we further analyzed levels of the four markers after adjustment for BMI as well as gender and age. Consequently, adiponectin and leptin levels were not significantly

different between the two groups any more, whereas fetuin-A and RBP4 levels remained significant ( $P = 0.0004$  and  $P = 0.0001$ ) (Table 5)

### Adiponectin, leptin, fetuin-A and RBP4 levels in patients with mild and severe disease

At the time of diagnosis, severity of the disease was assessed by spread of infiltrates on chest radiographs (Table 6). Small infiltrates affecting less than 3 of the 6 lung zones and large ones affecting more, categorized the patients into two subgroups (= mild and severe disease) half-and-half.

After adjustment for gender and age, adiponectin levels were higher and leptin levels were lower in patients with large infiltrates than in those with small infiltrates ( $P = 0.0033$  and  $P = 0.0020$ ). Interestingly, differences in the levels of these two adipokines between small and large infiltrates were significant respectively ( $P = 0.0061$  and  $P = 0.0040$ ), even after adjustment for BMI as well as gender and age (Table 7). Leptin/adiponectin ratio was lower, or adiponectin/leptin ratio was higher, in patients with large infiltrates than in those with small infiltrates independent of BMI ( $P = 0.0002$ ). None of the markers were associated with the presence of cavity on the chest radiographs (data not shown).

### Adiponectin, leptin, fetuin-A and RBP4 levels in patients with active TB before, during and at the end of anti-TB treatment

Figure 1 shows plasma values at the time points before (0 month), during (2 months) and at the end (7 months) of anti-TB treatment. Mean values in men ( $N = 41$ ) and women ( $N = 43$ ) of the no-symptom group are shown as a reference, in which gender difference was observed in leptin levels and leptin/adiponectin ratio ( $P < 0.0001$ ).

Overall differences of the measurements during anti-TB treatment in all of these four markers were statistically significant by repeated-measures ANOVA ( $P < 0.01$ ). Post-hoc analysis showed that adiponectin levels increased transiently ( $P = 0.0004$ ; 0 month vs. 2 months) and then decreased close to the reference range by the end of treatment ( $P < 0.0001$ ; 2 months vs. 7 months). Leptin levels remained low throughout the treatment course, though gradually elevated ( $P = 0.0226$ ; 0 month vs. 2 months). Initial low levels of fetuin-A and RBP4 significantly improved during treatment ( $P = 0.0001$  and  $P = 0.0016$ ; 0 month vs. 2 months), almost reaching the reference range by the end in concert with reduced CRP levels.

## Discussion

We assessed the clinical significance of four metabolic markers, adiponectin, leptin, fetuin-A and RBP4 in patients with active TB, analyzing them in relation to classical nutritional and inflammatory parameters, BMI and CRP, severity of disease and treatment course. BMI is known to be lower in patients with active TB than in control subjects [1,2]. After effective treatment, weight often increases but patients may remain underweight [11].

Plasma levels of adiponectin were inversely correlated with BMI in concordance with previous results [11,12]. The adiponectin levels tended to be elevated in the active-disease group characterized by low BMI, though it did not reach significant levels, which was also shown by others [29]. Interestingly in our study, adiponectin levels were significantly higher in severe disease with extensive pulmonary lesions than in mild disease, even after adjustment for BMI. Adiponectin as a modulator of inflammation in a variety of diseases has recently been highlighted [30]. For instance, in critically ill patients, adiponectin levels appear to be

transiently suppressed at the initial phase and then gradually elevated at the recovery phase [31,32]. The plasma concentrations in patients with active TB were further increased after starting treatment and then decreased close to the reference range by the end of treatment. Elevated adiponectin levels in chronic inflammatory diseases may be explained by compensatory response to the underlying disease as well as concomitant low body fat mass, which is postulated by others [33,34]. A study designed to measure alteration of adiponectin and BMI simultaneously throughout the treatment period would be able to characterize it further.

In most recent reports, leptin levels are low in TB [29,35–38], though other earlier or smaller studies have shown conflicting results [39–42]. In the present study, using a commercial ELISA, significantly lower levels of leptin were demonstrated in patients with active TB, which could be mostly explained by marked undernutrition in our disease population. Within the active-disease group, however, correlation between leptin and BMI was less clear. BMI-independent regulation of plasma leptin concentrations should also be taken into consideration in TB at least in part [13,37]. This idea is also supported by an *ex vivo* study by others demonstrating that continuous exposure of IL-1 or TNF- $\alpha$  provides a signal to downregulate leptin in human adipose tissue [43], though acute inflammation such as sepsis may rather upregulate circulating leptin levels transiently [44–46]. In addition to relatively high levels of adiponectin, low levels of leptin were observed in patients with large infiltrates, even after adjustment for BMI. This is concordant with a recent study showing that leptin levels were low in severe TB disease [29]. We have further demonstrated that low leptin/adiponectin ratio, or high adiponectin/leptin ratio is characteristic to severe TB disease in this study. This ratio was originally proposed as an atherogenic index indicating a balance between the two markers bearing apparently opposite functions in inflammation [47]. Our findings support the idea that suppressed production of leptin may be detrimental to host defense against TB by virtue of impairment of Th1 cell-mediated immunity [13,29,48]. After starting treatment, leptin levels were slightly elevated, but remained low during the treatment period. This is also compatible with reports made by others [37,38], although the mechanism remains unknown. Long-lasting low levels of leptin may be attributed to individual predisposition to TB or delayed recovery from wasting disease.

In our study, fetuin-A levels were considerably low in TB even after adjustment for BMI. Soon after starting treatment, the levels were increased in inverse proportion to the decrease in CRP. In TB, fetuin-A may be downregulated by at least dual mechanisms, strongly mediated by underlying inflammation [21] and partly controlled by depleted liver fat due to wasting or malnutrition [18]. Low fetuin-A levels may also result in impairment of macrophage function to kill the pathogen and ectopic calcification possibly in TB lesions [49,50].

RBP4 levels were also low in TB even after adjustment for BMI. Throughout the treatment course, the levels were gradually elevated close to the reference range inversely with the decrease in CRP. These findings are supported by a recent report demon-

strating that RBP4 rapidly decreases during acute inflammation, possibly acting as a negative acute phase reactant, similar to fetuin-A, albumin and prealbumin [21,51,52]. This may partly explain a close positive correlation with fetuin-A demonstrated in the active-disease group. In addition to dual regulation of RBP4 by underlying inflammation and low body fat mass, reduced renal function is also known to cause retention of the circulating levels, such that further caution is needed to interpret RBP4 measurement in disease state [53].

Our study has several limitations. Firstly, many types of nutrients including micronutrients are essential to the human body but the potential interplay between each component of nutrients was not within our scope at that time. Secondly, since change of BMI was not measured during treatment, direct comparison of improved BMI with the corresponding marker levels was not possible. Thirdly, blood was collected during the daytime without enforced fasting. Although, of course, this increases the variance of measurements, it can be inferred that daytime variations on circulating adipokines and leptin [54] are not as large as to seriously affect conclusive results of comparisons within and between groups in this study. Finally, computer tomography, which has advantages over chest radiography as an imaging tool, was not available in our setting.

Overall, our data and recent literature would suggest that all of the four markers tested are controlled partly by low fat store and partly by inflammation in TB but their regulatory mechanisms are more or less different and interactions with other relevant factors including insulin sensitivity and cellular immunity are worth further investigation. In particular, leptin, adiponectin and their ratio may be promising markers for severity of the wasting disease. Since nutritional intervention has a potential to improve prognosis of intractable TB such as HIV co-infection and MDR-TB, large-scale prospective studies using selected biomarkers to investigate metabolic contributors to disease phenotype are desired. The more fully we understand the mechanisms linking diet, health, and disease, the more effective will be our ability to design optimal interventions.

## Supporting Information

**Table S1** Pairwise correlations between four tested markers. (DOC)

## Acknowledgments

We thank Tokie Totsu and Fumi Toshioka for their technical assistance. The authors thank Kazuko Tanabe D.V.M. and Mr. John Crosskey for their critical reading of this manuscript.

## Author Contributions

Conceived and designed the experiments: N. Keicho IM TT N. Kobayashi SS. Performed the experiments: IM. Analyzed the data: N. Keicho IM NTLH TS. Contributed reagents/materials/analysis tools: IM TT NTLH SS MH PHT LTL. Wrote the paper: N. Keicho.

## References

1. Tverdal A (1986) Body mass index and incidence of tuberculosis. *Eur J Respir Dis* 69: 355–362.
2. Schaible UE, Kaufmann SH (2007) Malnutrition and infection: complex mechanisms and global impacts. *PLoS Med* 4: e115.
3. Prentice AM, Gershwin ME, Schaible UE, Kusch GT, Victora CG, et al. (2008) New challenges in studying nutrition-disease interactions in the developing world. *J Clin Invest* 118: 1322–1329.
4. Cegielski JP, McMurray DN (2004) The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals. *Int J Tuberc Lung Dis* 8: 286–298.
5. Dai G, McMurray DN (1998) Altered cytokine production and impaired antimycobacterial immunity in protein-malnourished guinea pigs. *Infect Immun* 66: 3562–3568.
6. Leung CC, Lam TH, Chan WM, Yew WW, Ho KS, et al. (2007) Lower risk of tuberculosis in obesity. *Arch Intern Med* 167: 1297–1304.
7. Dooley KE, Chaisson RE (2009) Tuberculosis and diabetes mellitus: convergence of two epidemics. *Lancet Infect Dis* 9: 737–746.
8. Mustad S, Haynes EN (2007) Biomarkers of obesity and subsequent cardiovascular events. *Epidemiol Rev* 29: 96–114.

9. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, et al. (2001) Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. *J Clin Endocrinol Metab* 86: 3815–3819.
10. Pitoimbo C, Araujo EP, De Souza CT, Parça JC, Geloneze B, et al. (2006) Amelioration of diet-induced diabetes mellitus by removal of visceral fat. *J Endocrinol* 191: 699–706.
11. Klempel MC, Varady KA (2011) Reliability of leptin, but not adiponectin, as a biomarker for diet-induced weight loss in humans. *Nutr Rev* 69: 145–154.
12. Kuo SM, Halpern MM (2011) Lack of association between body mass index and plasma adiponectin levels in healthy adults. *Int J Obes (Lond)* 35: 1487–1494.
13. Malli F, Papaioannou AI, Gourgoulidis KI, Daniil Z (2010) The role of leptin in the respiratory system: an overview. *Respir Res* 11: 152.
14. Klimcakova E, Kovacicova M, Stich V, Langin D (2010) Adipokines and dietary interventions in human obesity. *Obes Rev* 11: 446–456.
15. Tanaka T, Sakurada S, Kano K, Takahashi E, Yasuda K, et al. (2011) Identification of tuberculosis-associated proteins in whole blood supernatant. *BMC Infect Dis* 11: 71.
16. Denecke B, Gräber S, Schäfer C, Heiss A, Wöljke M, et al. (2003) Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. *Biochem J* 376: 135–145.
17. Mori K, Emoto M, Yokoyama H, Araki T, Teramura M, et al. (2006) Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. *Diabetes Care* 29: 468.
18. Stefan N, Hennige AM, Staiger H, Macham J, Schick F, et al. (2006) Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. *Diabetes Care* 29: 853–857.
19. Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, et al. (2008) Fetuin-A induces cytokine expression and suppresses adiponectin production. *PLoS Onc* 3: e1765.
20. Dasgupta S, Bhattacharya S, Biswas A, Majumdar SS, Mukhopadhyay S, et al. (2010) NF-kappaB mediates lipid-induced fetuin-A expression in hepatocytes that impairs adipocyte function affecting insulin resistance. *Biochem J* 429: 451–462.
21. Gangneux C, Daveau M, Hiron M, Derambure C, Papaconstantinou J, et al. (2003) The inflammation-induced down-regulation of plasma Fetuin-A (alpha2HS-Glycoprotein) in liver results from the loss of interaction between long C/EBP isoforms at two neighbouring binding sites. *Nucleic Acids Res* 31: 5957–5970.
22. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, et al. (2005) Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. *Nature* 436: 356–362.
23. Vitkova M, Klimcakova E, Kovacicova M, Valle C, Moro C, et al. (2007) Plasma levels and adipose tissue messenger ribonucleic acid expression of retinol-binding protein 4 are reduced during caloric restriction in obese subjects but are not related to diet-induced changes in insulin sensitivity. *J Clin Endocrinol Metab* 92: 2330–2335.
24. Marshall WJ (2008) Nutritional assessment: its role in the provision of nutritional support. *J Clin Pathol* 61: 1083–1088.
25. van Lattow M, Fawzi WW, Scahna RD (2003) Triple trouble: the role of malnutrition in tuberculosis and human immunodeficiency virus co-infection. *Nutr Rev* 61: 81–90.
26. Schultz DR, Arnold PI (1990) Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen. *Semin Arthritis Rheum* 20: 129–147.
27. Hang NT, Lien LT, Kobayashi N, Shimbo T, Sakurada S, et al. (2011) Analysis of factors lowering sensitivity of interferon- $\gamma$  release assay for tuberculosis. *PLoS One* 6: e23806.
28. Sakurada S, Hang NT, Ishizuka N, Toyota E, Hung LD, et al. (2012) Inter-rater agreement in the assessment of abnormal chest X-ray findings for tuberculosis between two Asian countries. *BMC Infect Dis* 12: 31.
29. Santucci N, D'Attilio L, Kovalevski L, Bozza V, Besedovsky H, et al. (2011) A multifaceted analysis of immune-endocrine-metabolic alterations in patients with pulmonary tuberculosis. *PLoS One* 6: e26363.
30. Robinson K, Prins J, Venkatesh B (2011) Clinical review: adiponectin biology and its role in inflammation and critical illness. *Crit Care* 15: 221.
31. Langouche L, Vander Perre S, Frystyk J, Flyvbjerg A, Hansen TK, et al. (2009) Adiponectin, retinol-binding protein 4, and leptin in protracted critical illness of pulmonary origin. *Crit Care* 13: R112.
32. Walkley AJ, Rice TW, Kontar J, Ouchi N, Shibata R, et al. (2010) Plasma adiponectin and mortality in critically ill subjects with acute respiratory failure. *Crit Care Med* 38: 2329–2334.
33. Moriconi N, Kraenzlin M, Müller B, Keller U, Nusbaumer CP, et al. (2006) Body composition and adiponectin serum concentrations in adult patients with cystic fibrosis. *J Clin Endocrinol Metab* 91: 1586–1590.
34. Sood A (2010) Obesity, adipokines, and lung disease. *J Appl Physiol* 108: 744–753.
35. Schwenk A, Hodgson L, Rayner CF, Griffin GE, Macallan DC (2003) Leptin and energy metabolism in pulmonary tuberculosis. *Am J Clin Nutr* 77: 392–398.
36. van Lattow M, van der Meer JW, West CE, van Crevel R, Somba RD (2005) Interleukin-6 and human immunodeficiency virus load, but not plasma leptin concentration, predict anorexia and wasting in adults with pulmonary tuberculosis in Malawi. *J Clin Endocrinol Metab* 90: 4771–4776.
37. van Crevel R, Karyadi E, Netea MG, Verboef H, Nekwan RH, et al. (2002) Decreased plasma leptin concentrations in tuberculosis patients are associated with wasting and inflammation. *J Clin Endocrinol Metab* 87: 758–763.
38. Buyukoglan H, Gulmez I, Kelestimur F, Kart L, Oymak FS, et al. (2007) Leptin levels in various manifestations of pulmonary tuberculosis. *Mediators Inflamm* 2007: 64859.
39. Yuksel I, Sencan M, Dokmetas HS, Dokmetas I, Ataseven H, et al. (2003) The relation between serum leptin levels and body fat mass in patients with active lung tuberculosis. *Endocr Res* 29: 257–264.
40. Cakir B, Yonem A, Guler S, Odabasi E, Demirbas B, et al. (1999) Relation of leptin and tumour necrosis factor alpha to body weight changes in patients with pulmonary tuberculosis. *Horm Res* 52: 279–283.
41. Bornstein SR, Preas HL, Chrousos GP, Saffedini AF (1998) Circulating leptin levels during acute experimental endotoxemia anti-inflammatory therapy in humans. *J Infect Dis* 178: 887–890.
42. Kim JH, Lee CT, Youn HI, Song J, Shin WG, et al. (2010) Relation of ghrelin, leptin and inflammatory markers to nutritional status in active pulmonary tuberculosis. *Clin Nutr* 29: 512–8.
43. Bruun JM, Pedersen SB, Kristensen K, Richelsen B (2002) Effects of pro-inflammatory cytokines and chemokines on leptin production in human adipose tissue in vitro. *Mol Cell Endocrinol* 190: 91–99.
44. Arnalich F, Lopez J, Codocco R, Jim M, Madero R, et al. (1999) Relationship of plasma leptin to plasma cytokines and human survival in sepsis and septic shock. *J Infect Dis* 180: 908–911.
45. Gualillo O, Eiras S, Lago F, Dieguez C, Casanueva FF (2000) Elevated serum leptin concentrations induced by experimental acute inflammation. *Life Sci* 67: 2433–2441.
46. Wallace AM, Sattar N, McMillan DC (2000) The co-ordinated cytokine/hormone response to acute injury incorporates leptin. *Cytokine* 12: 1042–1045.
47. Satoh N, Naruse M, Usui T, Tagami T, Suganami T, et al. (2004) Leptin-to-adiponectin ratio as a potential atherogenic index in obese type 2 diabetic patients. *Diabetes Care* 27: 2488–2490.
48. Wickland GW, Florquin S, Chan ED, Lecmans JC, Weijer S, et al. (2005) Pulmonary Mycobacterium tuberculosis infection in leptin-deficient ob/ob mice. *Int Immunol* 17: 1399–1408.
49. Jahne-Dechent W, Schäfer C, Ketteler M, McKee MD (2008) Mineral chaperones: a role for fetuin-A and osteopontin in the inhibition and regression of pathologic calcification. *J Mol Med (Berl)* 86: 379–389.
50. Jersmann HP, Dransfield I, Hart SP (2003) Fetuin/alpha2-HS glycoprotein enhances phagocytosis of apoptotic cells and macrophage apoptosis by human macrophages. *Clin Sci (Lond)* 105: 273–278.
51. Koch A, Weiskirchen R, Sanson E, Zimmermann HW, Voigt S, et al. (2010) Circulating retinol binding protein 4 in critically ill patients before specific treatment: prognostic impact and correlation with organ function, metabolism and inflammation. *Crit Care* 14: R179.
52. Fuhman MP, Charney P, Mueller CM (2004) Hepatic proteins and nutrition assessment. *J Am Diet Assoc* 104: 1258–1264.
53. Ingenbleek Y, Van Den Schrieck HG, De Nayer P, De Visscher M (1975) Albumin, transferrin and the thyroxine-binding prealbumin/retinol-binding protein (TBPA-RBP) complex in assessment of malnutrition. *Clin Chim Acta* 63: 61–67.
54. Gavrilu A, Peng CK, Chan JL, Mienus JE, Goldberger AL, et al. (2003) Diurnal and ultradian dynamics of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. *J Clin Endocrinol Metab* 88: 2838–2843.